Rituximab, @entity3118 , @entity786 , and @entity2664 : a new, highly active chemoimmunotherapy regimen for XXXX .

@entity1 @entity137 @entity41 @entity2664 @entity786 @entity1072 @entity2262 @entity3118 @entity1398 @entity281
PURPOSE: The addition of monoclonal antibodies to chemotherapy has significantly improved treatment of @entity1072 ( @entity1072 ). Based on excellent results with the chemotherapy-only regimen @entity3118 , @entity786 , and @entity2664 (FCM), we built a new chemoimmunotherapy combination--rituximab plus FCM (R-FCM). We report a phase II clinical trial consisting of an initial treatment with R-FCM followed by rituximab maintenance. @entity1 AND METHODS: Seventy-two untreated @entity1072 @entity1 age 70 years or younger received rituximab 500 mg/m(2) on day 1 (375 mg/m(2) the first cycle), @entity3118 25 mg/m(2) IV on days 1 to 3, @entity786 200 mg/m(2) on days 1 to 3, and @entity2664 6 mg/m(2) IV on day 1, given at 4-week intervals with up to six cycles supported with colony-stimulating factor. @entity1 achieving response received maintenance with rituximab 375 mg/m(2) every 3 months for 2 years. RESULTS: The overall response, @entity41 ( @entity41 ) -negative complete response (CR), @entity41 -positive CR, and partial response rates were 93%, 46%, 36%, and 11%, respectively. Severe @entity1398 developed in 13% of @entity1 . Major and minor @entity281 were reported in 8% and 5% of cycles, respectively. Advanced clinical stage, del(17p), or increased serum @entity2262 levels correlated with a lower CR rate. CONCLUSION: R-FCM is highly effective in previously untreated @entity1072 , with an 82% CR rate and a high proportion of @entity41 -negative CRs (46%). Treatment @entity137 is acceptable. Parameters correlating with a lower response rate were advanced clinical stage, high serum @entity2262 levels, and del(17p). Based on these results, R-FCM warrants further investigation in randomized clinical trials.
